Advancing long-term survival in ALK+ mNSCLC: Value of upfront Lorlatinib based on the CROWN 7y data (KSMO 2026) - Sep 22, 2026 - Pres time: Sep 3, 2026; 05:00 PM - 05:40 PM; Location: Room E; "Sponsored by Pfizer"
Non Small Cell Lung Cancer • Solid Tumor
|